PepGen Inc. (PEPG)
PepGen develops treatments for severe neuromuscular diseases, starting with myotonic dystrophy type 1. It last closed at $3.88 on Nov 17, down 7.40% on the day. The average 12-month price target from 3 analysts is $15.00 (+286.6% from the last close), with a high of $20.00 and a low of $10.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $278K, the largest $143K.
Key Stats
Last 12 monthsNot reported for this period.
From PEPG's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on PEPG in the past 90 days. The average target is $15.00, with a high of $20.00 and a low of $10.00, compared with the last close of $3.88.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 13 | Guggenheim | Maintained | Buy | $15 |
| Nov 11 | Wedbush | Maintained | Buy | $10 |
| Sep 9 | HC Wainwright & Co. | Reiterated | Buy | $20 |
| Jun 16 | Craig-Hallum | Initiated | Buy | $11 |
Technical Analysis
The stock is 20% above its 20 day and 27% above its 50 day average. It is 25% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 59). The nearest support is the Pivot S1 at $3.60, and the nearest resistance the Pivot at $3.90.
| RSI (14) | 58.55 | Middle of its range | Neutral |
| MACD | 0.47 | Above its signal line | Bullish |
| Stochastic | 45.6 | Middle of its range | Neutral |
| ADX (14) | 26.9 | Trending up | |
| Williams %R | -60.7 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 51.9 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +57.7% | Change over 10 sessions | Bullish |
| ATR (14) | $0.54 | Typical daily range, 13.9% of price |
| RSI (14) | 60.89 | Strong, overbought above 70 | Neutral |
| MACD | 0.14 | Above its signal line | Bullish |
| Stochastic | 43.1 | Middle of its range | Neutral |
| ADX (14) | 20.6 | Weak trend | |
| Williams %R | -60.5 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 170.9 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +30.2% | Change over 10 sessions | Bullish |
| ATR (14) | $0.78 | Typical daily range, 20.0% of price |
What happened before
See how PEPG did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How PEPG has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.
Whale Options Flow
90DNo whale options trades in PEPG in the last 90 days.
Dark Pool
30DPEPG Institutional Ownership
Full report →- ▲45 buying vs 30 selling
- ▲Held by funds +3.2 pts
- ▲Funds holding +12
- ▼Superinvestors: 0 added, 4 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 84 | 72 | +16.7% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 78.4% | 75.2% | +3.2 pts |
| New / increased | 20 / 25 | 7 / 21 | +60.7% |
| Reduced / sold out | 22 / 8 | 25 / 27 | −42.3% |
| Put/call ratio | 0.00 | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PEPG is in one of them and how their past PEPG trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PEPG in an article yet. Here's the latest on the wider market.
About PepGen
PepGen is a biotechnology company based in Boston, Massachusetts, that develops treatments for severe neuromuscular and neurologic diseases. Its lead candidate, PGN-EDODM1, is being developed for myotonic dystrophy type 1, a multi-system muscle disease with no approved therapies. The company's proprietary delivery platform uses peptides designed to carry short strands of genetic material into muscle and other cells, aiming to reach the cell nucleus. Its treatments remain in clinical trials and are intended for patients with these conditions.
- Headquarters
- Boston, MA



